Stock Events

Stock Events

Kiora Pharmaceuticals 

$2.53
55
-$0.04-1.56% Thursday 20:00

Statistics

Day High
2.71
Day Low
2.53
52W High
3.29
52W Low
1.765
Volume
94,850
Avg. Volume
-
Mkt Cap
9.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.86
-0.57
-0.28
0.01
Expected EPS
-0.47
Actual EPS
N/A

Financials

22.44%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
32.04MRevenue
7.19MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KPRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Regeneron Pharmaceuticals competes in the development of treatments for eye diseases, directly competing with Kiora's focus on ophthalmic diseases.
Novavax
NVAX
Mkt Cap1.46B
Novavax, while primarily known for vaccines, is expanding into therapeutic areas that could overlap with Kiora's research interests.
Bausch Health Companies
BHC
Mkt Cap1.89B
Bausch Health Companies, through its eye health division, competes in the same ophthalmic market as Kiora Pharmaceuticals.
Biogen
BIIB
Mkt Cap29.53B
Biogen's expansion into therapies for neurological conditions includes research into diseases that can affect vision, overlapping with Kiora's interests.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology sector, competing with Kiora Pharmaceuticals.
Pfizer
PFE
Mkt Cap149.38B
Pfizer has a diverse portfolio that includes treatments for conditions potentially overlapping with Kiora's focus areas.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its pharmaceuticals and medical devices divisions, competes in various healthcare sectors, including eye health.
Novartis
NVS
Mkt Cap292.07B
Novartis has a significant ophthalmology division, directly competing with Kiora Pharmaceuticals in developing treatments for eye diseases.

About

Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Show more...
CEO
Dr. Brian M. Strem Ph.D.
Employees
12
Country
United States
ISIN
US49721T5074

Listings

STU
DE
7EY.STU
MU
DE
7EY.MU
F
DE
7EY.F
BOATS
BOATS
KPRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Kiora Pharmaceuticals stock price today?▼
The current price of KPRX is $2.53 USD — it has decreased by -1.56% in the past 24 hours. Watch Kiora Pharmaceuticals stock price performance more closely on the chart.
What is Kiora Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kiora Pharmaceuticals stocks are traded under the ticker KPRX.
Is Kiora Pharmaceuticals stock price growing?▼
KPRX stock has fallen by -0.78% compared to the previous week, the month change is a -4.17% fall, over the last year Kiora Pharmaceuticals has showed a -20.94% decrease.
What is Kiora Pharmaceuticals market cap?▼
Today Kiora Pharmaceuticals has the market capitalization of 9.31M
When is the next Kiora Pharmaceuticals earnings date?▼
Kiora Pharmaceuticals is going to release the next earnings report on August 07, 2026.
What were Kiora Pharmaceuticals earnings last quarter?▼
KPRX earnings for the last quarter are -0.58 USD per share, whereas the estimation was -0.71 USD resulting in a +18.31% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kiora Pharmaceuticals revenue for the last year?▼
Kiora Pharmaceuticals revenue for the last year amounts to 32.04M USD.
What is Kiora Pharmaceuticals net income for the last year?▼
KPRX net income for the last year is 7.19M USD.
How many employees does Kiora Pharmaceuticals have?▼
As of June 20, 2026, the company has 12 employees.
In which sector is Kiora Pharmaceuticals located?▼
Kiora Pharmaceuticals operates in the Health & Wellness sector.
When did Kiora Pharmaceuticals complete a stock split?▼
The last stock split for Kiora Pharmaceuticals was on June 11, 2024 with a ratio of 1:9.
Where is Kiora Pharmaceuticals headquartered?▼
Kiora Pharmaceuticals is headquartered in Encinitas, United States.